Merck & Co., Inc. (MRK)
Healthcare · Drug Manufacturers - General · United States
As of 2026-06-22 · Source: yfinance · Market: closed_weekend · Cache TTL 360 min
Performance
| 1 Day | +1.41% |
| 1 Month | +2.19% |
| 3 Months | +0.86% |
| YTD | +8.48% |
| 1 Year | +44.06% |
| 52-Week High | $125.14 |
| 52-Week Low | $76.66 |
Fundamentals
| Market Cap | $285,215,358,976 |
| P/E (Trailing) | 32.53 |
| P/E (Forward) | 12.06 |
| EPS (TTM) | $3.55 |
| Dividend Yield | 2.99% |
| Beta | 0.22 |
| Revenue (TTM) | $65,768,001,536 |
| Profit Margin | 13.59% |
About Merck & Co., Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-29